Table 2.
Biomarker comparison of gastric and esophageal adenocarcinoma by Immunohistochemistry
| Gastric adenocarcinoma |
Esophageal adenocarcinoma |
||||
|---|---|---|---|---|---|
| Target Biomarker | Total | % Actionable | Total | % Actionable | P value |
| TOP2A (+) | 507 | 67 | 377 | 86 | <0.01 |
| TUBB3 (−) | 126 | 84.1 | 106 | 67.9 | <0.01 |
| ERCC1 (−) | 447 | 64.2 | 349 | 67.1 | |
| RRM1 (−) | 553 | 63.8 | 434 | 61.8 | |
| TS (−) | 548 | 62.4 | 433 | 60.7 | |
| PTEN (−) | 577 | 58.4 | 478 | 57.9 | |
| PGP (−) | 479 | 54.1 | 378 | 47.1 | |
| TOPO1 (+) | 543 | 46 | 433 | 54.7 | <0.01 |
| MGMT (−) | 576 | 40 | 471 | 51 | <0.01 |
| SPARC (+) | 584 | 15.4 | 477 | 34.4 | <0.01 |
| PDGFR (+) | 157 | 22.3 | 73 | 28.8 | |
| cMET (+) | 208 | 22.1 | 192 | 27.1 | |
| TLE3 (+) | 213 | 9.4 | 201 | 20.4 | <0.01 |
| HER2 (+) | 586 | 4.6 | 488 | 12.5 | <0.01 |
| cKIT (+) | 368 | 4.3 | 273 | 3.3 | |
| PR (+) | 559 | 3.2 | 451 | 3.1 | |
| ER (+) | 560 | 1.6 | 452 | 0 | |
| AR (+) | 559 | 0.7 | 449 | 0 | |